Video

Dr. Yu on the Drawbacks of Radiation Therapy in Prostate Cancer

Author(s):

James B. Yu, MD, associate professor, therapeutic oncology, director, Prostate and Genitourinary Cancer Radiotherapy Program, Yale Cancer Center, discusses drawbacks of radiation therapy in prostate cancer.

James B. Yu, MD, associate professor, therapeutic oncology, director, Prostate and Genitourinary Cancer Radiotherapy Program, Yale Cancer Center, discusses drawbacks of radiation therapy in prostate cancer.

Radiation therapy has become more advanced over the last few years, as researchers are better at tracking the tumor and delivering high doses of therapy while sparing normal tissue. With that being said, there are still challenges with this modality, Yu says. Side effects are still seen in patients, largely depending on the site of radiation.

For example, if radiation is delivered near the spinal cord, neurologic deficits can occur. Radiation near the bowels can cause gastrointestinal toxicities like severe diarrhea. The prostate sits in front of the rectum with the urethra and the bladder in close proximity, so prostate cancer is particularly challenging. There are multiple important organs nearby that radiation oncologists need to spare.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Addressing Unmet Needs in HER2+ Metastatic BTC
Video

Addressing Unmet Needs in HER2+ Metastatic BTC

Apr 18th 2025 - Apr 19th 2026

online-activity
Community Oncology Connections™: Case Discussions in TNBC…Navigating the Latest Advances and Impact of Disparities in Care | North Carolina
Video

Community Oncology Connections™: Case Discussions in TNBC…Navigating the Latest Advances and Impact of Disparities in Care | North Carolina

Apr 17th 2025 - May 23rd 2025

online-activity
Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Minnesota
Video

Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Minnesota

Apr 17th 2025 - May 23rd 2025

online-activity